A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

Also called NCT01225081

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01225081
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01225081. Randomized; quadruple masking; primary purpose treatment. Start 2010-09-15 (actual); primary completion 2012-04-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ipragliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Pioglitazone
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01225081
Content hash
0434b9af3622ad9021bb9e02be4e9ee755f2133ee478d16ae95d471be8bc0eaf